Previous
Next
ARCHIVE
№4' 2018
ENDOCRINOLOGYInternational Medical Journal, Vol. 24., Iss. 4, 2018, P. 70−75.
THE USE OF PHOSPHODIESTERASE TYPE 5 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ERECTILE DYSFUNCTION
State Enterprise "Institute of Endocrinology and Metabolism named after V. P. Komisarenko, NAMS of Ukraine", Kyiv, Ukraine
Erectile dysfunction is one of the most common complications of diabetes and may be a predictor of its development. Testosterone deficiency and the severity of erectile dysfunction independently of each other are associated with a decrease in the quality of life of patients with type 2 diabetes: the deterioration of physical function, social and vitality, general health. To study the effectiveness of the use of phosphodiesterase type 5 inhibitors (sildenafil, tadalafil and vardenafil) in men with type 2 diabetes and erectile dysfunction, a study was conducted, which included 89 patients aged 39−69 years who had a permanent sexual partner. Patients were divided into 3 groups in accordance with the prescribed drug. The results of the study indicate that the administration of sildenafil led to a significant improvement in the "Erectile Function" indicator compared to the pre−treatment index by 5.31 points, tadalafil −− by 5.8 points; Varedenafil −− by 8.3 points. Adverse reactions such as facial flushing, nasal congestion, headache, and throat irritation occurred in a small number of patients, had a mild severity and did not require discontinuation of the drug. The results of the study confirm the high efficacy of sildenafil, tadalafil and vardenafil in patients with type 2 diabetes and erectile dysfunction. The frequency of adverse reactions in our patients was low and comparable in the three groups examined.
Key words: type 2 diabetes mellitus, erectile dysfunction, phosphodiesterase inhibitors.